Oral sumatriptan-induced myocardial infarction.
BACKGROUND
Sumatriptan has been used in the treatment of migraine and other vascular headaches since 1993 in the United States. Its side effects include chest pains in 3% to 8% of patients who have known cardiac risk factors. This is a case report of a 45-year-old woman with no history of cardiac risk factors who had a myocardial infarction after her monthly dose of oral sumatriptan.


METHODS
The patient was examined in the emergency room, evaluated by electrocardiography, and serial evaluations of cardiac enzymes over the next 24 h. She was admitted to the cardiology ward. A cardiac catherization and additional laboratory studies were performed the following day.


RESULTS
The catherization revealed normal heart function, but a 60% to 70% non-flowing stenosis within the first septal perforator. Laboratory indices for cardiac risk were within normal ranges.


CONCLUSIONS
Patients without cardiac risk factors may experience myocardial infarction following an oral dose of sumatriptan.
Hack
Jason B
JB
Pitt County Memorial Hospital, East Carolina University, Greenville, NC 27850, USA. hackj@mail.ecu.edu
D006328:Cardiac Catheterization; D002637:Chest Pain / Q000139:chemically induced; D004562:Electrocardiography / Q000187:drug effects; D004798:Enzymes / Q000097:blood; D005260:Female; D006334:Heart Function Tests; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000503:physiopathology; D009206:Myocardium / Q000201:enzymology; D017366:Serotonin Receptor Agonists / Q000009:adverse effects*; D018170:Sumatriptan / Q000009:adverse effects*
D004798:Enzymes; D017366:Serotonin Receptor Agonists; D018170:Sumatriptan